Circassia pockets $21.8M in second VC round

Goldman Sachs and Invesco Perpetual have signed on as new investors in Circassia, a UK biotech exploring ways to control immune responses. They helped put up $21.8 million in Circassia's second round of venture capital. Circassia's lead products target allergies using its T-cell epitope desensitization technology, which was originally developed at Imperial College London.

"We have made good progress advancing our anti-allergy products during the last year, and successfully completing this funding, particularly in the current challenging market conditions, is a strong vote of confidence from a syndicate of world-class investors," says Steve Harris, Circassia's CEO.

- check out the release for more

Suggested Articles

The planned takeover centers on ARQ 531, a BTK inhibitor that triggered durable responses in patients with B-cell malignancies.

At ASH, Dana-Farber researchers presented promising preclinical data on AMG 701, Amgen's long-lasting BiTE for multiple myeloma, but rivals loom.

The takeover, the first of Paul Hudson’s time as CEO, will give Sanofi an IL-2 drug it thinks can become a foundation of future cancer combinations.